Bhattacharya K, Orton RC, Qi X, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis. 2007; 30 (3): 350-357.
Correia CE, Bhattacharya K, Lee PJ, et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr. 2008; 88(5): 1272-1276.
Numbers at the data points represent the number of patients remaining on each product without becoming hypoglycemic at a given point in time.
Humphrey MS. The use of Glycosade to extend fasting tolerance and improve oral intake in GSD1b. Mol Genet Metab. 2009; 98: 89-118. CLOSED ACCESS
Maritz CM, Cousins A, Murphy E. Reduction in insulin response in a patient with GSD1 using a new modified starch: Case report. Mol Genet Metab.2009; 98: 39-88.
Mullally M, Eardley J, Gick J, Mundy H, Champion M. Retrospective evaluation of clinical practice: using a modified cornstarch in the management of glycogen storage disease. J Inherit Metab Dis. 2010; 33 (suppl 1): S1-S197.
Corrado MM, Ross KM, Brown LM, Correia CE, Weinstein DA. Assessment of safety and efficacy of extended release cornstarch therapy in glycogen storage disease type Ia. J Inherit Metab Dis. (2013); 36 (suppl 2): S5227-S5228.
Hubert-Buron A, Mollet-Boudjemline A, Voillot C, et al. Comparison of Glycosade and uncooked cornstarch (UCCS) for the treatment of hepatic glycogen storage disease type I (GSD I). Poster presented at IGSD, Heidelberg (2013).
Vitaflo is pleased to bring you the following lecture presentations which were recorded at the 1st Nutrition in Glycogen Storage Disease (GSD) Education Day held in Raleigh-Durham, North Carolina on September 19th, 2013. This one-day educational program for dietitians and other healthcare professionals included discussions on the nutritional management of GSD types I and III, current guidelines and practices for management using uncooked corn starch and Glycosade (Vitaflo®), as well as a review of the needs for protein in GSD type III.
Bhattacharya K, Mundy H, Lilburn MF, Champion MP, Morley DW, Maillot F. A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study. Orphanet J Rare Dis. 2015; 10 (1): 18.
Mean (+ /- SD) profile for seven paired starch loads for a) glucose and b) insulin. The median and interquartile range of areas under the curve for the first four hours of the study for c) glucose and d) insulin. Table for 3a and b indicates number of subjects still fasting at a given time, T in hours, for C = UCCS and W = Waxy maize heat modified strach. (Glucose area calculated above a baseline of 3.0 mmols/L).
Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, Porras LY, Mathew JT, Weinstein DA. Safety and Efficacy of Chronic Extended Release
Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, Porras LY, Mathew JT, Dambska M, and Weinstein DA. Safety and Efficacy of Long-Term Use of Extended Release Cornstarch Therapy for Glycogen Storage Disease Types 0, III, VI, and IX. Jour Nutr Ther. 2016;4:137-142.